Clinical Commander

Back to dossier
pulm.massive-hemoptysis.v1PRODUCTION
pulm.massive-hemoptysis.v1

Massive (Life-Threatening) Hemoptysis (acute airway emergency)

pulmonologyacuteadult
Hard-required inputs
0 / 11
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Acute AIRWAY EMERGENCY, adult. Confirm TRUE hemoptysis vs hematemesis vs pseudohemoptysis — the entry-classification gate; misclassification routes to the wrong engine (GI bleed / ENT). The killer is asphyxiation, not exsanguination (Earwood AFP 2015 PMID 25955625)

Inputs
1
Actions
0
Advance rule
Set
Advance when

True hemoptysis confirmed (not hematemesis/pseudohemoptysis)

Patient inputs (17)

Hypoxia from alveolar flooding = the lethal physiology; defines massive (Charya 2021 PMID 34527355)

Respiratory distress / work of breathing — airway-compromise severity

Hypotension → hemodynamic-massive trigger + resuscitation target

Tachycardia — shock surrogate during ongoing airway bleeding

Cause discrimination — bronchiectasis/CF, post-TB, mycetoma/aspergilloma, malignancy (Mal 2003 PMID 12816036; Allwood Respiration 2021 PMID 33401266)

Anticoagulation/antiplatelet amplifies any source and is reversible — first modifiable factor (Charya 2021 PMID 34527355)

INR/aPTT/fibrinogen/platelets — reversible coagulopathy is a treatable amplifier (Charya 2021 PMID 34527355)

Transfusion threshold + trend; volume status (Charya 2021 PMID 34527355)

Type & cross for transfusion / peri-procedural support

Massive defined by physiology — gas-exchange/hemodynamic compromise, or surrogate ≥150 mL single expectoration / ≥100 mL/h / >100-600 mL/24h (Earwood AFP 2015 PMID 25955625; Charya 2021 PMID 34527355)

Hemoptysis (frothy, bright red, alkaline, cough, respiratory history) vs hematemesis (acidic, dark/coffee-ground, food, GI history) vs pseudohemoptysis (nasopharyngeal/oral source) — the entry-classification gate (Earwood AFP 2015 PMID 25955625)

Lateralizes the bleeding lung and enables tamponade; rigid bronchoscopy preferred for true massive (airway control + suction) (Charya 2021 PMID 34527355)

AFB smear / Xpert MTB-RIF when TB / post-TB / mycetoma plausible (Allwood Respiration 2021 PMID 33401266)

ANCA / anti-GBM when pulmonary-renal or DAH pattern — diagnostic for vasculitic source (Flores-Suárez PMID 28752492)

DAH from ANCA vasculitis / anti-GBM — pulse steroids + immunosuppression, NOT BAE (PEXIVAS PMID 32053298; RAVE PMID 20647199; Flores-Suárez PMID 28752492)

Rapid bedside lateralization clue (side of infiltrate/mass) — low sensitivity, never the localization endpoint (Earwood AFP 2015 PMID 25955625)

Multidetector CT-angiography localizes side + bleeding vessel (bronchial vs pulmonary artery, Rasmussen, AVM) and maps it for BAE; yield is CONDITIONAL on active bleeding (Charya 2021 PMID 34527355)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (8)

8 need judgement
  • informationallife_threateningasphyxiation_or_airway_compromise
    Hemoptysis with hypoxia / respiratory distress / inability to clear the airway / hemodynamic compromise — physiologic-massive (asphyxiation, the lethal mechanism; can occur at ≈150 mL)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpulmonary_artery_source_not_BAE_amenable
    Rasmussen aneurysm (TB cavity), AVM/HHT, or iatrogenic Swan-Ganz/PA rupture — pulmonary-artery source (~5%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningongoing_bleeding_post_BAE_to_surgery
    Persistent/recurrent massive bleeding after BAE, or BAE failed/contraindicated/unavailable, or non-embolizable focal lesion
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdiffuse_alveolar_hemorrhage_respiratory_failure
    Diffuse alveolar hemorrhage (ANCA vasculitis / anti-GBM / SLE) — diffuse bilateral, falling Hgb, often pulmonary-renal, may have minimal expectorated blood, with respiratory failure
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremassive_vs_nonmassive_physiologic_trigger
    Volume surrogate (≥150 mL single expectoration / ≥100 mL/h / >100-600 mL/24h) OR any rate compromising gas-exchange/hemodynamics — the disposition gate (physiology > volume)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereanticoagulation_or_coagulopathy_amplifier
    Hemoptysis on anticoagulant/antiplatelet OR with lab coagulopathy (INR↑, low platelets/fibrinogen, DIC/sepsis/liver)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelocalized_bronchial_source_for_BAE
    CTA/angiography shows a localized bronchial-artery or nonbronchial-systemic culprit (~90% of cases)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatenegative_localization_in_quiescent_interval
    CTA + bronchoscopy negative/non-localizing performed AFTER bleeding has stopped — conditional-dependency caveat
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSoptionalDrives severity classification
Loading…

Recommended regimen

Massive hemoptysis — airway-first resuscitation → coagulopathy reversal + TXA → BAE → bronchoscopic tamponade → surgery (last resort)
axis: massive_hemoptysis_control_ladderstep 1 - Airway-first resuscitation + lung isolation (the asphyxiation pivot)
Selected step "Airway-first resuscitation + lung isolation (the asphyxiation pivot)" — Any physiologic-massive hemoptysis — gas-exchange or hemodynamic compromise. Performed BEFORE/CONCURRENT with localization (Charya 2021 PMID 34527355)
  • bleeding_side_down_lateral_decubitus_positioning
    first line
    positioning
    Bleeding lung DOWN (when side known/suspected) • positioning • continuous
    triggers: suspected_or_known_bleeding_side
    Protects the non-bleeding lung from soiling — asphyxiation, not exsanguination, is the killer (Charya 2021 PMID 34527355)
  • high_flow_oxygen_and_large_bore_suction
    first line
    oxygenation
    High-flow O2 to SpO2 ≥92%; continuous large-bore suction • inhaled • continuous
    triggers: hypoxia
    Maintain oxygenation while clearing airway blood (Charya 2021 PMID 34527355)
  • selective_intubation_lung_isolation
    first line
    airway_isolation
    Large single-lumen ETT (≥8.0) to good lung, OR bronchial blocker, OR double-lumen tube • airway • once
    triggers: airway_compromise, massive_ongoing_bleed
    Isolate/protect the non-bleeding lung; single-lumen + blocker is often more practical emergently than a DLT (Charya 2021 PMID 34527355)
  • massive_transfusion_protocol_pRBC_FFP_platelets
    rescue
    blood_product
    Balanced resuscitation per institutional MTP; correct fibrinogen with cryoprecipitate • IV • as needed
    triggers: hemorrhagic_shock, falling_hemoglobin
    Support oxygen-carrying capacity + correct dilutional/consumptive coagulopathy; blood products have no single RxCUI → non_pharm (Charya 2021 PMID 34527355)

ed playbook — drug actions (5)

  1. 1. bleeding-side-down lateral decubitus + high-flow O2 + large-bore suction
    Positioning + O2 to SpO2 ≥92% • positioning/inhaled • continuous
    trigger: Physiologic-massive hemoptysis
    Protect the good lung — asphyxiation is the killer (Charya 2021 PMID 34527355)
  2. 2. selective intubation / lung isolation
    Large single-lumen ETT to good lung ± bronchial blocker or DLT • airway • once
    trigger: Airway compromise / ongoing massive bleed
    Lung isolation before imaging if physiology demands (Charya 2021 PMID 34527355)
  3. 3. tranexamic acid
    IV 1 g over 10 min + nebulized 500 mg-1 g • IV + nebulized • IV q8h; neb tid
    trigger: Active hemoptysis
    Adjunct antifibrinolytic — RCT/meta evidence in non-massive (Wand PMID 30321510; Tsai PMID 32661913); never replaces airway control/BAE
  4. 4. reverse anticoagulation/coagulopathy
    4F-PCC + vitamin K1 10 mg IV (warfarin); idarucizumab/andexanet (DOAC); protamine (heparin); platelets/DDAVP (antiplatelet/uremic) • IV • as indicated
    trigger: Anticoagulant on board or lab coagulopathy
    Remove the modifiable amplifier (Charya 2021 PMID 34527355)
  5. 5. norepinephrine
    0.05-0.5 µg/kg/min IV to MAP ≥65 • IV • continuous
    trigger: Shock during ongoing bleeding
    Hemodynamic support during resuscitation (Charya 2021 PMID 34527355)

Auto-drafted A&P note

ed

Subjective

- Possible entry pathways: Expectoration of blood / blood-streaked sputum — quantify volume + rate (Earwood AFP 2015 PMID 25955625); Hemoptysis WITH hypoxia / respiratory distress / hypotension — physiologic-massive trigger (Charya 2021 PMID 34527355); Red-flag escalation from pulm.bronchiectasis.core.v1 / pulm.tuberculosis.v1 / pulm.abpa.v1 when bleeding becomes life-threatening.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Massive (Life-Threatening) Hemoptysis (acute airway emergency)** (pulm.massive-hemoptysis.v1).
Phenotype framing: Hemoptysis vs hematemesis vs pseudohemoptysis; MASSIVE vs non-massive; BRONCHIAL ARTERY (~90%, systemic pressure, BAE-amenable) vs PULMONARY ARTERY (~5% — Rasmussen in TB cavity, AVM in HHT, iatrogenic Swan-Ganz: PA-targeted coil/balloon NOT bronchial BAE) vs nonbronchial systemic collaterals; cause discrimination (bronchiectasis/CF, TB/post-TB, mycetoma, malignancy, DAH/vasculitis, AVM, mitral stenosis, iatrogenic) — full LR table in .depth.md (Mal 2003 PMID 12816036; Earwood AFP 2015 PMID 25955625)
Scope: Acute AIRWAY EMERGENCY, adult. Confirm TRUE hemoptysis vs hematemesis vs pseudohemoptysis — the entry-classification gate; misclassification routes to the wrong engine (GI bleed / ENT). The killer is asphyxiation, not exsanguination (Earwood AFP 2015 PMID 25955625)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Massive hemoptysis — airway-first resuscitation → coagulopathy reversal + TXA → BAE → bronchoscopic tamponade → surgery (last resort)** — step "Airway-first resuscitation + lung isolation (the asphyxiation pivot)".
1. bleeding_side_down_lateral_decubitus_positioning Bleeding lung DOWN (when side known/suspected) positioning continuous (positioning, first line) — Protects the non-bleeding lung from soiling — asphyxiation, not exsanguination, is the killer (Charya 2021 PMID 34527355)
2. high_flow_oxygen_and_large_bore_suction High-flow O2 to SpO2 ≥92%; continuous large-bore suction inhaled continuous (oxygenation, first line) — Maintain oxygenation while clearing airway blood (Charya 2021 PMID 34527355)
3. selective_intubation_lung_isolation Large single-lumen ETT (≥8.0) to good lung, OR bronchial blocker, OR double-lumen tube airway once (airway_isolation, first line) — Isolate/protect the non-bleeding lung; single-lumen + blocker is often more practical emergently than a DLT (Charya 2021 PMID 34527355)
4. massive_transfusion_protocol_pRBC_FFP_platelets Balanced resuscitation per institutional MTP; correct fibrinogen with cryoprecipitate IV as needed (blood_product, rescue) — Support oxygen-carrying capacity + correct dilutional/consumptive coagulopathy; blood products have no single RxCUI → non_pharm (Charya 2021 PMID 34527355)

Setting playbook (ed) — Confirm true hemoptysis, triage MASSIVE vs non-massive on physiology, protect the airway (bleeding-side-down + lung isolation), reverse coagulopathy + give TXA, localize with CTA, and activate IR (BAE) + thoracic surgery + ICU simultaneously
5. bleeding-side-down lateral decubitus + high-flow O2 + large-bore suction Positioning + O2 to SpO2 ≥92% positioning/inhaled continuous — Physiologic-massive hemoptysis (Protect the good lung — asphyxiation is the killer (Charya 2021 PMID 34527355))
6. selective intubation / lung isolation Large single-lumen ETT to good lung ± bronchial blocker or DLT airway once — Airway compromise / ongoing massive bleed (Lung isolation before imaging if physiology demands (Charya 2021 PMID 34527355))
7. tranexamic acid IV 1 g over 10 min + nebulized 500 mg-1 g IV + nebulized IV q8h; neb tid — Active hemoptysis (Adjunct antifibrinolytic — RCT/meta evidence in non-massive (Wand PMID 30321510; Tsai PMID 32661913); never replaces airway control/BAE)
8. reverse anticoagulation/coagulopathy 4F-PCC + vitamin K1 10 mg IV (warfarin); idarucizumab/andexanet (DOAC); protamine (heparin); platelets/DDAVP (antiplatelet/uremic) IV as indicated — Anticoagulant on board or lab coagulopathy (Remove the modifiable amplifier (Charya 2021 PMID 34527355))
9. norepinephrine 0.05-0.5 µg/kg/min IV to MAP ≥65 IV continuous — Shock during ongoing bleeding (Hemodynamic support during resuscitation (Charya 2021 PMID 34527355))

Non-pharmacologic actions:
- Two large-bore IVs ± central access (Charya 2021 PMID 34527355)
- Activate interventional radiology for emergent BAE (Kim PMID 17052307)
- Activate thoracic surgery + interventional pulmonology in parallel (Charya 2021 PMID 34527355)
- Airborne isolation if TB/post-TB plausible (Allwood Respiration 2021 PMID 33401266)
- Do NOT delay airway control for imaging in physiologic-massive (Charya 2021 PMID 34527355)

AVOID / contraindication checks:
-  BAE — avoid embolizing the anterior spinal artery (spinal cord ischemia risk); identify spinal/radiculomedullary branches before particle release (Charya 2021 PMID 34527355)
-  bronchial BAE does NOT control a PULMONARY ARTERY source (Rasmussen aneurysm / AVM / iatrogenic Swan Ganz rupture, ~5%) — requires PA targeted coil/balloon; mis targeting wastes the lethal window (Charya 2021 PMID 34527355; Mal 2003 PMID 12816036)
-  DAH from ANCA vasculitis / anti GBM is NOT a BAE target — definitive therapy is pulse glucocorticoid + cyclophosphamide/rituximab ± plasma exchange (PEXIVAS PMID 32053298; RAVE PMID 20647199)
-  TXA is an ADJUNCT in massive hemoptysis — trial evidence (Wand PMID 30321510; Tsai PMID 32661913) is in NON massive; never substitute TXA for airway control + BAE in true massive (Charya 2021 PMID 34527355)
-  do NOT delay airway protection / lung isolation for localization imaging in physiologic massive hemoptysis — asphyxiation kills before exsanguination (Charya 2021 PMID 34527355)
-  emergency lobectomy/pneumonectomy mortality ~20 40% vs elective ~5 18% — operate electively after stabilization + BAE where feasible (Kim Respirology 2006 PMID 17052307)
-  nebulized TXA can cause asymptomatic bronchoconstriction — have a SABA available; long term safety unestablished (Gopinath PMID 36410494; Ye PMID 39841268)

Monitoring

Regimen monitoring:
- continuous SpO2 + airway patency + work-of-breathing (Charya 2021 PMID 34527355)
- serial hemoglobin + coagulation panel + fibrinogen during active bleeding / MTP (Charya 2021 PMID 34527355)
- post-BAE rebleed surveillance — overall ~10-30%, higher with aspergilloma / CPA / complicated pneumoconiosis (Kim PMID 17052307; Okuda PMID 26718145; Lee PMID 18210312)
- repeat CTA / bronchoscopy if rebleed → repeat-BAE vs surgery decision (Kim PMID 17052307)
- DAH on immunosuppression — monitor for respiratory failure + infection while on pulse steroids/cyclophosphamide/rituximab (PEXIVAS PMID 32053298)
- route to underlying-disease engine for definitive long-term management once airway secured (Allwood Respiration 2021 PMID 33401266)

Setting (ed) monitoring:
- Continuous SpO2 / cardiac monitor / airway patency (Charya 2021 PMID 34527355)
- Serial Hgb + coags + fibrinogen (Charya 2021 PMID 34527355)
- Reassess bleeding rate every few minutes during active hemorrhage (Charya 2021 PMID 34527355)

Follow-up plan: Route BACK to the underlying-disease engine for definitive management once airway secured — bronchiectasis airway clearance (pulm.bronchiectasis.core.v1), TB therapy (pulm.tuberculosis.v1), ABPA/aspergilloma steroids+antifungal (pulm.abpa.v1), vasculitis maintenance immunosuppression, malignancy oncology (onc.lung-cancer.core.v1); recurrence-prevention + repeat-BAE/surgery planning (Allwood Respiration 2021 PMID 33401266)
- Close-out criterion: Underlying-disease engine engaged + recurrence-prevention plan documented

Monitoring phase: Rebleed surveillance (BAE rebleed ~10-30%, higher with aspergilloma / complicated pneumoconiosis / chronic pulmonary aspergillosis), airway/gas-exchange, serial Hgb + coags, repeat CTA/bronchoscopy if rebleed, treat underlying disease; DAH → titrate immunosuppression + monitor for respiratory failure (Kim PMID 17052307; Okuda PMID 26718145; Lee PMID 18210312; PEXIVAS PMID 32053298)

Disposition

Current setting: ed — Confirm true hemoptysis, triage MASSIVE vs non-massive on physiology, protect the airway (bleeding-side-down + lung isolation), reverse coagulopathy + give TXA, localize with CTA, and activate IR (BAE) + thoracic surgery + ICU simultaneously

Disposition criteria:
- ICU mandatory for all true massive hemoptysis (Charya 2021 PMID 34527355)
- Interventional suite (BAE) then ICU; OR if BAE fails/contraindicated (Kim PMID 17052307)
- Non-massive with controlled bleeding + benign workup → monitored admission, route to cause engine

Escalation triggers (move to higher acuity):
- Asphyxiation / airway compromise / refractory hypoxia → immediate lung isolation + ICU (Charya 2021 PMID 34527355)
- Ongoing bleeding despite reversal + TXA → emergent BAE (Kim PMID 17052307)
- BAE unavailable / failed → bronchoscopic tamponade bridge + emergency surgery (Charya 2021 PMID 34527355)
- DAH pattern + respiratory failure → ICU + pulse immunosuppression (PEXIVAS PMID 32053298)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hemoptysis with hypoxia / respiratory distress / inability to clear the airway / hemodynamic compromise — physiologic-massive (asphyxiation, the lethal mechanism; can occur at ≈150 mL)
- [LIFE_THREATENING] Rasmussen aneurysm (TB cavity), AVM/HHT, or iatrogenic Swan-Ganz/PA rupture — pulmonary-artery source (~5%)
- [LIFE_THREATENING] Persistent/recurrent massive bleeding after BAE, or BAE failed/contraindicated/unavailable, or non-embolizable focal lesion

Citations

- No single society "massive hemoptysis" guideline exists — evidence floor: Charya life-threatening hemoptysis ICU review (J Thorac Dis 2021; PMID 34527355) + Earwood hemoptysis evaluation/management (AFP 2015; PMID 25955625) + CHEST nebulized-TXA RCT (Wand 2018; PMID 30321510) + Cochrane antifibrinolytics (2016; PMID 27806184) + BAE long-term series (Kim Respirology 2006 PMID 17052307; Lee Acta Radiol 2008 PMID 18210312) + PEXIVAS/RAVE for DAH (NEJM 2020 PMID 32053298; NEJM 2010 PMID 20647199); all confirmed current 2026-05-16 [PMID:34527355](https://pubmed.ncbi.nlm.nih.gov/34527355/)
- Cited evidence (PMID 25955625) [PMID:25955625](https://pubmed.ncbi.nlm.nih.gov/25955625/)
- Cited evidence (PMID 12816036) [PMID:12816036](https://pubmed.ncbi.nlm.nih.gov/12816036/)
- Cited evidence (PMID 17052307) [PMID:17052307](https://pubmed.ncbi.nlm.nih.gov/17052307/)
- Cited evidence (PMID 18210312) [PMID:18210312](https://pubmed.ncbi.nlm.nih.gov/18210312/)

Last reconciled with current guidelines: 2026-05-16.
References
  • No single society "massive hemoptysis" guideline exists — evidence floor: Charya life-threatening hemoptysis ICU review (J Thorac Dis 2021; PMID 34527355) + Earwood hemoptysis evaluation/management (AFP 2015; PMID 25955625) + CHEST nebulized-TXA RCT (Wand 2018; PMID 30321510) + Cochrane antifibrinolytics (2016; PMID 27806184) + BAE long-term series (Kim Respirology 2006 PMID 17052307; Lee Acta Radiol 2008 PMID 18210312) + PEXIVAS/RAVE for DAH (NEJM 2020 PMID 32053298; NEJM 2010 PMID 20647199); all confirmed current 2026-05-16 — PMID:34527355
  • Cited evidence (PMID 25955625) — PMID:25955625
  • Cited evidence (PMID 12816036) — PMID:12816036
  • Cited evidence (PMID 17052307) — PMID:17052307
  • Cited evidence (PMID 18210312) — PMID:18210312